Symphysis Medical

Independence | Comfort | Quality of Life

Developing an innovative drainage technology to treat malignant pleural effusions (MPE)

Read more...
Better Outcomes

Better
Outcomes

 

Incorporates an active component that will significantly shorten the treatment duration of MPE compared to current catheter devices.

 

Patient Centric

Patient
Centric

A user-friendly design to promote patient independence, comfort and quality of life.


Cost Effective

Healthcare
Savings

Reduces the costs associated with long-term home drainage and acute readmissions to hospital.


 

SymPhysis Medical

Located in Galway, Ireland

 

linked to experts internationally

 

MedTech Rising: Emerging Medtech Company…

Posted in News by Symphysis Medical

5th December, 2022

SymPhysis Medical were delighted to be nominated for the Emerging Medtech Company of the Year Award at the Irish Medtech Awards in December 2022. The Irish Medtech Association is the...

Read more

SymPhysis Medical wins HealthTech Innova…

Posted in News by Symphysis Medical

24th November, 2022

The SymPhysis Medical team were delighted to win Best Indigenous Healthcare Start-up at the The HealthTech Innovation Awards in Dublin on 23 November. HealthTech Ireland is an independent trade association for...

Read more
SymPhysis Medical graduates from MedTech Innovator

SymPhysis Medical graduates from MedTech…

Posted in News by Symphysis Medical

1st November, 2022

In October 2022, SymPhysis Medical graduated from MedTech Innovator, a global accelerator program for medical device, digital health and diagnostic companies. Having won the highly competitive International Pitch event in Dublin...

Read more

SymPhysis Medical wins the MedTech Innov…

Posted in News by Mary Faherty

4th May, 2022

SymPhysis Medical were thrilled to win the MedTech Innovator Dublin International Pitch event, which took place in Dublin on 25 & 26 April 2022. MedTech Innovator is a global competition and...

Read more

MPE By Numbers

Mesothelioma

Affects ~90% of patients with mesothelioma.

Lung Cancer

Affects ~ 35% of patients with lung cancer.

Breast Cancer

Affects ~ 16% of patients with breast cancer.

Lymphoma

Affects ~ 11% of patients with lymphoma.